Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 14;19(9):2768.
doi: 10.3390/ijms19092768.

Drug Repurposing of Metabolic Agents in Malignant Glioma

Corinna Seliger  1 , Peter Hau  2
Affiliations
Review

Drug Repurposing of Metabolic Agents in Malignant Glioma

Corinna Seliger et al. Int J Mol Sci. .

Abstract

Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient's metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed.

Keywords: NSAR; disulfiram; drug repurposing; glioblastoma; glioma; lonidamine; metformin; statin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The founding sponsors had no role in the design of the manuscript, interpretation of data, writing of the manuscript, and in the decision to publish the results.

References

    1. Schlegel U., Weller M., Westphal M. Neuroonkologie. 2nd ed. Thieme; Stuttgart, Germany: 2003.
    1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. Who Classification of Tumours of the Central Nervous System. 4th ed. IARC Press; Lyon, Frence: 2016.
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Stupp R., Hegi M.E., Gorlia T., Erridge S.C., Perry J., Hong Y.K., Aldape K.D., Lhermitte B., Pietsch T., Grujicic D., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated mgmt promoter (centric eortc 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100–1108. doi: 10.1016/S1470-2045(14)70379-1. - DOI - PubMed
    1. Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources